

University of Groningen

Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma

Kluiver, Joost; Slezak-Prochazka, Izabella; de Jong, Debora; Smigielska, Katarzyna; Kortman, Gertrud; Winkle, Melanie; Rutgers, Bea; Koerts, Jasper; Visser, L.; Diepstra, Arjan

Published in:
Oncotarget

DOI:
[10.18632/oncotarget.6165](https://doi.org/10.18632/oncotarget.6165)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2016

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Kluiver, J., Slezak-Prochazka, I., de Jong, D., Smigielska, K., Kortman, G., Winkle, M., ... van den Berg, A. (2016). Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma. *Oncotarget*, 7(3), 2391-2400. DOI: 10.18632/oncotarget.6165

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma

Izabella Slezak-Prochazka^{1,2,*}, Joost Kluiver^{1,*}, Debora de Jong¹, Katarzyna Smigielska-Czepiel¹, Gertrud Kortman¹, Melanie Winkle¹, Bea Rutgers¹, Jasper Koerts¹, Lydia Visser¹, Arjan Diepstra¹, Bart-Jan Kroesen¹ and Anke van den Berg¹

¹ Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

² Biosystems Group, Institute of Automatic Control, Silesian University of Technology, Gliwice, Poland

* These authors have contributed equally to this work

Correspondence to: Anke van den Berg, **email:** a.van.den.berg01@umcg.nl

Keywords: B-cell lymphoma, NIAM, Ago2-IP, miR-155, TBRG1

Received: July 16, 2015

Accepted: October 04, 2015

Published: October 19, 2015

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Several studies have indicated an important role for miR-155 in the pathogenesis of B-cell lymphoma. Highly elevated levels of miR-155 were indeed observed in most B-cell lymphomas with the exception of Burkitt lymphoma (BL). However, the molecular mechanisms that underlie the oncogenic role of miR-155 in B-cell lymphoma are not well understood. To identify the miR-155 targets relevant for B-cell lymphoma, we performed RNA immunoprecipitation of Argonaute 2 in Hodgkin lymphoma (HL) cells upon miR-155 inhibition and in BL cells upon ectopic expression of miR-155. We identified 54 miR-155-specific target genes in BL cells and confirmed miR-155 targeting of *DET1*, *NIAM*, *TRIM32*, *HOMEZ*, *PSIP1* and *JARID2*. Five of these targets are also regulated by endogenous miR-155 in HL cells. Both overexpression of miR-155 and inhibition of expression of the novel miR-155 target gene *NIAM* increased proliferation of BL cells. In primary B-cell lymphoma NIAM-positive cases have significant lower levels of miR-155 as compared to NIAM-negative cases, suggesting that *NIAM* is also regulated by miR-155 in primary B-cell lymphoma. Thus, our data indicate an oncogenic role for miR-155 in B-cell lymphoma which involves targeting the tumor suppressor *NIAM*.

INTRODUCTION

MiRNAs are short (21-23 nucleotides) non-coding RNA molecules that mediate posttranscriptional silencing of their target genes [1]. MiRNA-dependent expression regulation is crucial in cellular processes including cell cycle, apoptosis and proliferation. Deregulated miRNA levels have been observed in various hematological malignancies, including B-cell lymphomas [2].

MiR-155 is one of the most frequently studied miRNAs in normal and malignant B-cells. Studies in mice revealed an important regulatory role of miR-155 in diverse aspects of the immune response including B-cell development. Most germinal center (GC) B cells express the primary transcript of miR-155, *BIC / MIR155HG*, and

harbor high levels of the mature miR-155 in the course of the GC response [3]. Several studies implicate an important role for miR-155 in the pathogenesis of B-cell leukemia and lymphoma. Overexpression of miR-155 driven by the B-cell-specific E μ -enhancer induced pre-B-cell lymphoma in miR-155 transgenic mice [4]. In a similar study induction of miR-155 in murine lymphoid tissues caused a clonal, transplantable pre-B-cell malignancy that was dependent on miR-155 expression [5]. In human, high miR-155 levels were observed in GC B cell-derived lymphomas like Hodgkin lymphoma (HL), chronic lymphocytic leukemia, primary mediastinal B-cell lymphoma and diffuse large B-cell lymphoma [6-8]. In contrast, Burkitt lymphoma (BL) is characterized by very low miR-155 levels [9]. Over the past few years

several miR-155 target genes involved in functioning of normal hematopoietic cells have been identified [10-12]. However, it is largely unknown which target genes are involved in the pathogenesis of B-cell lymphoma.

To identify miR-155 target genes relevant for the pathogenesis of B-cell lymphoma we performed Ago2-immunoprecipitation in B-cell lymphomas with high and low miR-155 expression levels. Next, we tested which of the identified targets were involved in the oncogenic effect of miR-155 overexpression and showed that downregulation of NIAM reproduced the enhanced growth phenotype of miR-155 overexpression. Finally, we show that miR-155 levels are in general high in NIAM-negative B-cell lymphomas and vice versa, supporting a role for miR-155 mediated downregulation of NIAM in the pathogenesis of B-cell lymphoma.

RESULTS

Unbiased genome-wide identification of miR-155 target genes in B-cell lymphoma

To determine the target genes of miR-155 in B-cell lymphoma we performed Ago2-RIP-Chip following two strategies. On one hand we stably overexpressed miR-155 in a BL cell line (ST486) known to have low miR-155 levels. On the other hand we inhibited miR-155 with a miRNA-155 sponge construct in 2 HL cell lines (KM-H2 and L1236), both known to have high miR-155 levels. Overexpression of miR-155 in ST486 cells was confirmed by qRT-PCR and revealed a ~500 fold increase in miR-155 levels (Suppl. Fig. S1A). These levels are comparable to the endogenous miR-155 levels observed in HL cell lines KM-H2 and L1236. Efficiency of the IP procedure was confirmed by Western blot and miRNA qRT-PCR (Suppl. Fig. S1B-S1D).

We defined the miRNA targetome as all transcripts that were ≥ 2 -fold enriched in the immunoprecipitated (IP) fraction compared to the total (T) fraction (IP fold enrichment, IP/T ratio ≥ 2). The number of Ago2-IP-enriched probes was similar in all three cell lines, ranging between 12.5%-17.7% of the consistently-expressed probes (Suppl. Table S1). To identify the miR-155-specific targets in ST486 cells we determined which probes had an IP/T ratio of ≥ 2 -fold in miR-155-transduced cells and showed an at least 2-fold lower IP/T ratio in EV-transduced cells. In total 64 probes (3.5% of all IP enriched probes) detecting 54 different genes fulfilled these criteria (3 probes did not correspond to any known gene, Suppl. Table S2). Similar analyses were performed for the two HL cell lines, i.e. probes with a ≥ 2 -fold IP enrichment in EV-transduced cells and an at least 2-fold lower IP enrichment in miR-155 sponge-transduced cells. This revealed only 19 (0.5% of all IP probes) and 6 (0.3%

of all IP probes) probes that fulfill these criteria in KM-H2 and L1236 cells, respectively (data not shown).

Next, we performed gene set enrichment analysis (GSEA) to determine whether specific gene sets were enriched in the IP fractions. We noted that 40-75% of the 20 most enriched gene sets corresponded to miRNA binding site motif gene sets, indicating an efficient enrichment of miRNA target genes in all IP fractions. As a result of the overexpression of miR-155 in ST486 cells, the rank of the miR-155-binding site motif gene set was increased from 46th in EV-ST486 to 13th in miR-155-ST486 cells (Fig. 1A) (Suppl. Table S3). In HL cells, the EV-transduced lines already showed clear enrichment of miR-155 target genes in the IP fraction (Fig. 1A). However, the ranking of the miR-155-binding site motif set did not decrease clearly in KM-H2 (rank 25th to rank 24th) or L1236 (rank 8th to rank 9th) cells upon overexpression of the miR-155 sponge (Suppl. Tables S4, S5). Thus, GSEA shows that in ST486 cells miR-155 targets are enriched in the Ago2-IP fraction upon miR-155 overexpression, whereas HL cells do not show a clear depletion of miR-155 targets upon miR-155 inhibition. The GSEA results for the HL cell lines, as well as the more limited number of putative specific miR-155 targets, suggested that the miR-155 sponge did not effectively sequester all miR-155 molecules, probably because of the very high endogenous miR-155 expression levels in KM-H2 and L1236 cells (Fig. S1A).

Analysis of the IP/T ratios of the 54 ST486 miR-155 target genes in the HL cell lines, revealed enrichment for 45 out of 53 (85%) and 25 out of 43 (58%) target genes in EV-transduced L1236 and KM-H2 cells respectively, indicating that these targets are regulated by one or more miRNAs in the wild type HL cell lines (Suppl. Fig. S2). The other ST486 miR-155 targets were either not expressed in L1236 and KM-H2 cells (1 and 11), more mildly enriched ($1.5 \leq \text{IP/T} \leq 2$ for 3 and 10) or not enriched ($\text{IP/T} \leq 1.5$ for 5 and 8).

The enrichment of miR-155 targets in miR-155-ST486 compared to EV-ST486 cells ranged from 2.0 to 12.6 fold (Fig. 1B). *In silico* validation indicated that 26 out of 54 genes (48%) contained an 8-mer (AGCATTA) and 43 genes (80%) a 6-mer (GCATTA) miR-155 binding site in their 3'UTRs (Suppl. Table S2). Moreover, 33% (18 out of 54) of the identified genes were predicted to be miR-155 targets by TargetScan [13]. This is a significant increase as compared to the 1.7% predicted miR-155 targets among all expressed genes ($p < 0.0001$, Chi-square test). Thus, we identified 54 miR-155 target genes by overexpression of miR-155 of which the vast majority was also targeted by miRNAs in B-cell lymphoma cell lines with high endogenous levels of miR-155.

Validation of miR-155 target genes

We selected six genes identified by Ago2-RIP-

Chip in ST486 cells for validation, i.e. one known miR-155 target gene, Jumonji AT rich interactive domain 2 (*JARID2*), and the five genes with the highest Ago2-IP




Figure 1: Identification of miR-155 target genes using Ago2-immunoprecipitation. **A.** Gene set enrichment plot of the miR-155-binding site motif comparing the Ago2-IP fraction to the total fraction shows strong enrichment of miR-155 target genes in the IP fractions of miR-155-ST486, EV-L1236 and EV-KM-H2 cells. **B.** Overview of the 54 genes that were enriched more prominently in the Ago2-IP fraction of miR-155-ST486 cells compared to that of EV-ST486 cells. The names of the 6 genes selected for further analysis are indicated. Grey bars indicate genes that are predicted miR-155 targets according to TargetScan. The dashed line indicates the cutoff of 2-fold higher enrichment in the Ago2-IP fraction of miR-155-ST486 compared to EV-ST486 cells. The total list of genes is shown in Table S2. **C.** Five of the six selected genes are also enriched in the Ago2-IP fraction of HL cells. Shown are the IP/T (immunoprecipitated fraction/total fraction) ratios of the six selected miR-155 target genes. Five of these genes, *DET1*, *NIAM*, *HOMEZ*, *PSIP1* and *JARID2* also show IP/T>2 in EV-L1236 and EV-KM-H2 cells. *TRIM32* is not expressed in L1236 and 1.75 fold enriched in EV-KM-H2 cells. **D.** Schematic overview of 3'UTR or CDS (*HOMEZ*) regions with the positions of the predicted miR-155 binding sites indicated by the arrows (6-mer and 8-mer sites). For *NIAM* and *PSIP1*, the 3'UTR of the isoforms containing the miR-155 binding sites are shown (ENST00000441174 and NM_021144, respectively). **E.** All 6 selected genes, but not the EV control, are targeted by miR-155 in luciferase reporter assay. For each construct, the Renilla/Firefly luciferase (RL/FL) ratio upon co-transfection with the miR-155 precursor is shown relative to a negative control co-transfection that was set to 100%. P-values were calculated with an unpaired t-test (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). **F.** *DET1* protein level was decreased in miR-155-ST486 compared to EV-ST486 cells. Western blot for *DET1* relative to GAPDH, EV-ST486 was set as 1, the average of 2 experiments is shown.

enrichment upon miR-155 overexpression (>4-fold, Fig. 1B, Suppl. Table S2), i.e. De-Etiolated-1 homolog (*DETI*), Nuclear Interactor of ARF and Mdm2 (*NIAM*, the protein-coding transcript splice variant of the *TBRG1* locus), Tripartite motif-32 (*TRIM32*), Homeobox leucine zipper (*HOMEZ*) and PC4 and SFRS1 interacting protein 1 (*PSIP1*). We confirmed Ago2-IP enrichment in the HL EV-transduced cells for 5 of the 6 targets (Fig. 1C). The 6th gene, i.e. *TRIM32*, was not expressed in L1236 and was borderline enriched in KM-H2 cells (IP/T ratio = 1.75). For 4 out of the 5 miR-155 targets the IP enrichment was mildly decreased upon miR-155-sponge overexpression in L1236 and for 5 out of 6 in KM-H2 cells. This suggests that these genes are also targeted by endogenously expressed miR-155 in HL cells (Suppl. Fig. S2). To validate a direct interaction between miR-155 and these targets we cloned their predicted miR-155 binding sites into the psiCHECK2 luciferase vector. For *DETI*, *NIAM*, *TRIM32*, *PSIP1* and *JARID2* these sites were located in their 3'UTRs and for *HOMEZ* they were predicted in the coding sequence (Fig. 1D). For all 6 genes, co-transfection of the resulting luciferase constructs with a miR-155 precursor into ST486 wild-type cells resulted in significantly decreased relative luciferase levels (range 15-53%) compared to co-transfection with a negative control precursor (Fig. 1E). In addition, the highest Ago2-IP-enriched gene upon miR-155 overexpression in ST486 cells, i.e. *DETI*, showed a decreased protein level upon miR-155 induction in ST486 cells (Fig. 1F). Thus, we confirmed that *DETI*, *NIAM*, *TRIM32*, *HOMEZ*, *PSIP1* and *JARID2* are valid miR-155 target genes.

Both miR-155 overexpression and inhibition of miR-155 target NIAM result in enhanced cell growth

In line with an oncogenic role in B-cell lymphoma, overexpression of miR-155 in ST486 cells caused accelerated growth, resulting in ~2-fold increase in the percentage of GFP+ cells in 22 days (Fig. 2A). Consistent with the mild effects of the miR-155 sponge in the Ago2-IP experiments, no clear effects on cell growth were observed upon overexpression of the miR-155 sponge in HL cell lines L1236 and KM-H2 (data not shown).

To determine whether inhibition of any of the 6 validated miR-155 target genes could reproduce the miR-155 overexpression phenotype we generated two shRNA constructs per gene. For 5 of the 6 targets at least one of the 2 shRNAs showed a 50% reduction at the protein or RNA level (Suppl. Fig. S3A and S3B). For *HOMEZ* both shRNAs were not effective (data not shown). GFP competition assays using all shRNAs revealed that for only one of the miR-155 target genes, i.e. *NIAM*, an increased cell growth was observed. Inhibition of *NIAM* using *NIAMsh1* but not *NIAMsh2* increased the

number of GFP+ cells by ~50%, approximately half of the effect of miR-155 overexpression (Fig. 2B). To explain the discrepancy between the two *NIAM* shRNAs, we studied the expression pattern of *TBRG1* splice variants. Published RNA-seq data in BL cell line Mutu1 revealed that two isoforms were most abundant, i.e. isoform ENST000004411740 (the protein-coding transcript variant known as *NIAM* which contains a miR-155-binding site) and ENST00000473629 (non-coding *TBRG1* transcript with no miR-155-binding site) (Fig. 2C) [14]. The probe on our microarray that detects both isoforms (probe 1) showed signals ~8 times higher than the probe that specifically detects the miR-155-binding site containing *NIAM* transcript (probe 2) (Fig. 2D). However, only the latter probe detecting the *NIAM* transcript was enriched in the IP fraction (Fig. 2E). *NIAMsh1*, that phenocopied the miR-155 overexpression effect, was directed against the *NIAM* transcript and not the non-coding *TBRG1* transcript (Fig. 2C). This resulted in >60% downregulation of the *NIAM* transcript while the total *TBRG1* transcript levels were not affected (Fig. 2F and 2G). *NIAMsh2*, which was directed against both isoforms of the *TBRG1* locus, did not show any effect in the GFP competition assay. In line with this, *NIAMsh2* did not affect *NIAM* transcript levels (data not shown) possibly due to the much higher abundance of the non-protein-coding transcript. Despite several attempts we were not able to design a second effective shRNA targeting the 137nt exon 4 that is specific to the *NIAM* transcript. Thus, *NIAM* inhibition phenocopied the growth promoting effect of miR-155 overexpression although this was not confirmed with a second shRNA.

NIAM expression is inversely associated with miR-155 levels in B-cell lymphoma

To determine whether *NIAM* protein expression in primary B-cell lymphoma is inversely associated with the miR-155 expression level we analyzed primary cases of CLL (high miR-155), DLBCL (variable miR-155) and BL (low miR-155) by immunohistochemistry for *NIAM* and qRT-PCR for miR-155. Two of the 14 CLL cases (14%), 13 out of 17 (76%) DLBCL cases and all 10 BL cases stained positive for *NIAM* (Fig. 3A-3D, Suppl. Fig. S3C for validation of the antibody specificity). Among DLBCL, 75% of the ABC subtype and 78% of the GCB subtype were *NIAM*-positive. MiR-155 levels were significantly higher in *NIAM*-negative as compared to *NIAM*-positive lymphoma cases ($p < .0145$, Mann Whitney U test, Fig. 3E). Thus, these data support a miR-155-dependent regulation of *NIAM* protein expression in primary B-cell lymphoma.

DISCUSSION

MiR-155 is one of the most studied miRNAs in




Figure 2: Inhibition of miR-155 target NIAM phenocopies the effect of miR-155 overexpression. **A.** Overexpression of miR-155 enhanced growth of ST486 cells resulting in a ~2 fold increase in the percentage of GFP+ cells on day 22 post-transduction compared to day 4 (mixed model analysis, *** $p < 0.001$). **B.** The NIAM specific shRNA (NIAMsh1) that specifically inhibits the protein-coding isoform (NIAM) of the *TBRG1* locus enhanced growth of ST486 cells in the GFP competition assay (mixed model analysis, *** $p < 0.001$). **C.** Schematic overview of the two most abundant *TBRG1* isoforms. The position of the miR-155 binding site (miR-155), the region targeted by the shRNAs against NIAM (NIAMsh), the location of the two probes targeting transcripts of the *TBRG1* locus present on the microarray and the qRT-PCR products specific for NIAM and total *TBRG1* are indicated. **D.** The normalized signal intensity of probe 1 (detecting both *TBRG1* isoforms) was much higher than that of probe 2 (NIAM only) in ST486 cells. **E.** Probe 2 that specifically detected the NIAM transcript was strongly enriched in the targetome of miR-155-ST486 cells, whereas probe 1 that detected both isoforms was not enriched. **F.** QRT-PCR expression analysis confirms that NIAMsh1 can effectively target the NIAM transcript but has no impact on the total *TBRG1* transcript level **G.** The PCR products amplified in panel F and G are indicated in panel C. Expression is relative to *GAPDH*.

B-cell lymphoma. Over the past few years several miR-155 target genes were identified, however only a few were shown to be relevant for the pathogenesis of B-cell lymphoma. In this study we identified miR-155 targets in B-cell lymphoma and showed that growth of BL-derived ST486 cells was enhanced upon overexpression of miR-155. Phenotype copy experiments indicated that one of the identified miR-155 targets, i.e. NIAM, is involved in the miR-155-induced enhanced growth. The shRNAs against JARID2, PSIP1, TRIM32 and DET1 did not result in an enhanced cell growth indicating that these genes are unlikely to be involved in the enhanced growth phenotype. However, it might be that JARID2, PSIP1, TRIM32 and DET1 are involved in other miR-155-dependent phenotypes that were not studied.

We identified 54 miR-155 target genes using Ago2-RIP-Chip in ST486 cells with ectopic expression of miR-155. Meier et al. performed Ago2-RIP-Seq in embryonic kidney HEK293 cells with ectopic miR-155 expression and identified 100 miR-155 target genes [15]. In good concordance with our study, their list included 22 of the 54 genes we identified in ST486 cells, including *DET1*, *TRIM32*, *HOMER* and *JARID2*. These genes likely represent miR-155 targets common to various cell types. *NIAM* was not identified as a miR-155 target in HEK293 cells suggesting that *NIAM* might be a lymphoma-specific target gene.

We were not able to efficiently identify miR-155 target genes using the miR-155-sponge approach in HL cells. MiR-155 sponge transcripts were expressed and efficiently enriched in the Ago2-IP fraction [16], yet miR-

155 target genes were only very mildly depleted in the Ago2-IP fraction of miR-155 sponge-transduced HL cells. Although miRNA-sponges can function as very potent miRNA targets that specifically sequester the miRNA to prevent it from binding to endogenous targets it is very well possible that sponge transcript levels in this case were insufficient for complete sequestering of the very highly expressed miR-155 [16-18].

Dorsett et al. showed that low miR-155 levels in normal B cells result in increased expression of the miR-155 target gene Activation-Induced Cytidine Deaminase (*AICDA*) and this enhanced the frequency of *MYC* translocations [19]. Since *MYC* translocations are the hallmark of BL, it might be anticipated that the low miR-155 levels observed in BL are especially crucial at the initiation step of the malignant transformation of germinal center B cells. A recent follow-up study showed that mature B cells isolated from miR-155 deficient mice have higher p53 activity [20]. This was shown to be mediated in part by *AICDA* and in part by the miR-155 target *SOCS1*. In BL, the putative undesired activation of p53 via increased expression of the miR-155 target *SOCS1* needs to be blocked by direct or indirect inactivation of p53. In line with the proposed oncogenic role of miR-155, in this study we showed that ectopic miR-155 overexpression enhances the growth of BL cell line ST486. However, miR-155 most likely does not function as an oncogene in the pathogenesis of BL, since miR-155 levels in general are low in BL. This is in contrast to other subtypes of B-cell lymphoma that have strongly increased levels of miR-155 and do not depend on *AICDA*-driven




Figure 3: Inverse correlation between NIAM protein expression and miR-155 levels in primary cases of B-cell lymphoma. Sections from B-cell lymphoma cases with various levels of miR-155 were stained with anti-NIAM antibody. A. BL case positive for NIAM. B. CLL case negative for NIAM. C. A NIAM-positive and D. NIAM-negative DLBCL case. Representative images are shown. Image magnifications 400x. E. Significant differences in miR-155 levels were observed between primary B-cell lymphoma cases with or without NIAM protein expression (Mann Whitney U test, * $p < 0.05$). MiR-155 levels were determined by qRT-PCR and normalized to RNU49 levels.

MYC translocations, but may benefit from the miR-155-mediated suppression of *SOCS1* resulting in reduced p53 activity [6-8].

Inhibition of *NIAM* expression recapitulated, at least in part, the growth promoting phenotype induced by miR-155 overexpression in ST486 cells. We were not able to quantify the endogenous *NIAM* levels by Western blotting using the commercial *NIAM* antibody or a published *NIAM* antibody [21]. It should be noted that cellular *NIAM* levels are maintained at relative low levels due to Mdm2-dependent ubiquitination [22]. The inability to detect the endogenous *NIAM* also prevented a comparison between *NIAM* protein levels upon miR-155 overexpression and upon shRNA-based *NIAM* inhibition. Thus, we could not determine whether differences in the effects of miR-155 overexpression and *NIAM* knockdown are caused by differences in *NIAM* protein levels or due to other genes simultaneously targeted by miR-155.

We showed that *NIAM* protein expression inversely correlated with miR-155 levels in primary B-cell lymphoma. *NIAM* staining was predominantly cytoplasmic. This is in contrast to the results reported by Reed et al., who showed that *NIAM* is localized in the nucleus and bound to chromatin [23]. Nonetheless and similar to our study, *NIAM* was clearly localized in the cytoplasm of 2 pancreatic cell lines [21]. These different staining patterns indicate that *NIAM* can be both nuclear and cytoplasmic. Microarray studies indicated that *NIAM* transcript levels are lowered in various types of cancer, including B-cell lymphoma [22]. The tumor suppressive function of *NIAM* was confirmed in a recent study that showed that *NIAM*-deficient mice were predisposed to develop proliferative lesions, including early stage B-cell lymphoma [24]. Moreover, *NIAM* was shown to act as a tumor suppressor protein linked to the p53 pathway in several ways [22, 23]. It stimulated p53 activity by interacting with p53 regulators such as Mdm2 and Tip60 [23]. Exogenous *NIAM* stabilized p53 by binding to Mdm2 and preventing Mdm2-mediated p53 ubiquitylation, and association of *NIAM* with Tip60 increased p53 transactivation of the p21 promoter. In addition, exogenous *NIAM* was shown to inhibit cell proliferation independent of p53 [25]. It would be interesting to study whether the *NIAM*-mediated effect of miR-155 depends on decreased p53 activity.

In conclusion, we identified *NIAM* as a novel miR-155 target gene in B-cell lymphoma. Induction of miR-155 enhances growth of ST486 BL cells and our data indicate that this is at least in part caused by inhibition of *NIAM*. *NIAM* expression inversely correlated with miR-155 levels in primary B-cell lymphoma. Our data, together with the recent observation that *NIAM*-deficient mice are predisposed to malignant transformation suggest that *NIAM* is a crucial target for the oncogenic effects of miR-155 in B-cell lymphoma.

MATERIALS AND METHODS

Tissue samples

Individual diagnosis of the 10 BL, 14 CLL and 17 DLBCL samples were reviewed by an experienced hematopathologist for consistent morphology and immunophenotype according to the 2008 WHO classification [26]. Pediatric BL cases presented with an abdominal mass and were CD10+, BCL2- and MYC-breakpoint+. CLL cases were nodal and CD5+, CD23+, cyclinD1- with variable ZAP70 expression. Diffuse large B-cell lymphoma (DLBCL) cases were classified into ABC (8) or GCB (9) subtypes according to the Hans algorithm [27]. All protocols for obtaining human tissue samples were performed in accordance to the guidelines from the Institutional review board or Medical Ethical committee of the University Medical Center Groningen.

Cell lines

ST486, L1236 and KM-H2 cell lines were cultured as previously described [28, 29]. Cell lines were purchased from ATCC (ST486) or DSMZ (L1236 and KM-H2). Phoenix-ampho cells were cultured in DMEM supplemented with 10% fetal calf serum.

DNA constructs and viral transductions

To overexpress miRNA-155, the pre-miRNA with flanking sequences was amplified from genomic DNA using primers listed in Table S6. Insert was cloned into the retroviral MXW-PGK-IRES-GFP vector [30] using XhoI and EcoRI. To validate miRNA overexpression, GFP+ cells were sorted ~2 weeks after transduction using a MoFlo sorter (Dako cytometry). We inhibited miR-155 using a retrovirally expressed miR-155 sponge with 14 binding sites (Table S6) [16]. The 3'UTR of *DETI*, *TRIM32*, *JARID2*, *PSIP1*, *NIAM* and the ~300nt coding sequence fragment of *HOMEZ* containing the potential miR-155-binding sites were amplified from genomic DNA using primers listed in Table S6 and cloned into the psiCHECK2 vector (Promega, Madison, WI). To inhibit miR-155 target genes, shRNA oligos were designed (Table S6) and cloned into the retroviral pMDH1-PGK-GFP 2.0 vector [30]. The sequence of *NIAM*sh1 was based on a previous study [22]. Retroviral transductions were performed as previously described [28].

Quantitative RT-PCR

RNA isolation and miRNA-specific cDNA synthesis and qPCR were performed as previously

described [31, 32]. MiRNA levels were normalized to RNU48 or RNU49 levels. For quantification of *NIAM*, total *TBRG1*, *DET1*, *TRIM32*, *HOMEZ*, *PSIP1*, *JARID2*, cDNA was synthesized using random primers, dNTP mix and the Superscript II Reverse Transcriptase Kit (Life Technologies Europe BV, Bleiswijk, NL) according to manufacturer's instructions. The qPCR reactions for *NIAM* and total *TBRG1* were performed as previously described [28], *GAPDH* was used as a reference gene, primers are listed in Table S6. For *DET1*, *TRIM32*, *PSIP1* and *JARID2*, the qPCR reactions were performed using qPCR MasterMix Plus (Eurogentec, Liege, Belgium) and either Taqman Gene expression assays (Hs00894490_m1 for *DET1*, Hs00705875_s1 for *TRIM32*, Hs01045711_g1 for *PSIP1* and Hs01004460_m1 for *JARID2*, all Applied Biosystems) or designed primers and probe for detection of *HPRT* as described previously [33].

Ago2-RIP-Chip procedure

Immunoprecipitation of Ago2-containing RISC complexes was performed as described previously [34]. Briefly, cleared lysates of 20-30 million cells were incubated with protein G Sepharose beads (GE Healthcare) coated with anti-Ago2 antibody (Clone 2E12-1C9, Abnova, Taiwan) at 4°C overnight. Anti-IgG antibody was used as a negative control (Millipore BV, Amsterdam, The Netherlands). RNA was isolated for microarray and qRT-PCR analysis and protein lysates were prepared for Western blot. Western blot for Ago2 was performed as described previously [34]. RNA from the total and Ago2-IP fractions was analyzed using 44k Human Whole Genome Oligo microarrays (Agilent, Santa Clara, USA). Labeling and hybridization were performed with 100ng of total RNA using the two-color Quick Amp Labeling Kit (ST486) or Low Input Quick Amp Labeling Kit (L1236 and KM-H2) and Cyanine (Cy) 3 and 5 CTP Dye Packs according to the manufacturer's protocol (Agilent). The microarray data have been deposited in NCBI's Gene Expression Omnibus [35] and are accessible through GEO Series accession number GSE70939. Data were analyzed using GeneSpring GX version 12.5 (Agilent). Quantile normalization of the signals was performed. Probes not detected in more than half of the samples and that were inconsistent (more than 2 fold different) in Cy3 and Cy5 replicates of the same sample were filtered out. The averaged signals for Cy3 and Cy5 replicates were used to calculate the IP/T ratio for each sample.

Gene Set Enrichment Analysis

To determine which genes sets are significantly enriched in the Ago2-IP in comparison to the total fraction we performed Gene Set Enrichment Analysis using The Molecular Signatures Database (GSEA; [http://www.broad.](http://www.broad.mit.edu/gsea)

[mit.edu/gsea](http://www.broad.mit.edu/gsea)) [36]. If more than one probe was assigned for a certain gene, we selected the probe with the highest IP fold enrichment.

Transfection and luciferase assay

Luciferase assays were performed using the Promega Dual-Luciferase Reporter Assay System (Promega, Madison, WI) as described previously [37]. Briefly, two million ST486 cells were transfected with 4µg of each psiCHECK2 construct and co-transfected with 100nM miR-155 precursor or negative control #1 (both Ambion) using an Amaxa nucleofector device, program A23 (Amaxa, Gaithersburg, MD). Transfections were performed in triplicate and cell lysates were made 24h after transfection. Renilla to Firefly (RL/FL) luciferase ratios were calculated and compared to negative control (set at 100%). Significance was calculated using the t-test.

Western Blot

Western blot for DET1 was performed as previously described [38]. Immunoblots were incubated with mouse anti-DET1 antibody (clone 3G5, Genentech, San Francisco, CA) at a concentration of 1 µg/ml in 5% milk in Tris-buffered saline with Tween-20 (TBST) overnight at 4°C. Mouse anti-GAPDH antibody (clone 0411, 1:20,000, Santa Cruz, CA, USA) was used as a control. Western Blot for NIAM was performed using a rabbit polyclonal anti-NIAM antibody (18951-1-AP, Proteintech, Chicago, IL, USA) diluted 1:500 in 5% milk in TBST overnight at 4°C.

GFP competition assay

GFP expression was measured on a FACS Calibur flow cytometer (BD PharMingen) at day 3 or 4 post-transduction and monitored for three weeks tri-weekly. The percentage of GFP+ cells was analyzed using FlowJo software (version 7.6, Treestar, Ashland, OR); the value at day 3 or 4 was set to 1 and the fold difference per measurement was calculated. To determine whether cells with increased miR-155 or decreased TBRG1 levels grow significantly different from cells transduced with control vectors, we performed mixed model analysis on the relative percentages with the interaction between transduced cell type and day of measurement as fixed effects and day of measurements and the biological replicate measurements as within-subject variables in SPSS (version 22). Since the relative percentages were 1 on day 3 or 4 by definition, we analyzed the relative percentage -1 and did not include the intercept and the main effects of cell type and day of measurement in the model.

NIAM Immunohistochemistry

Sections of BL, CLL and DLBCL cases were cut (3µm) and staining was performed using a rabbit polyclonal anti-NIAM antibody (18951-1-AP, 1:25, Proteintech) in combination with microwave-citrate buffer (pH 6.0) antigen retrieval. Staining was visualized using a peroxidase coupled goat anti-rabbit secondary antibody (1:100), a peroxidase-coupled rabbit anti-goat tertiary antibody (1:100, both DAKO, Glostrup, Denmark), and 3,3-diaminobenzidine tetrachloride.

ACKNOWLEDGEMENTS

We thank prof. Dawn Quelle (The University of Iowa, USA) for valuable discussions and providing the anti-NIAM antibody.

CONFLICTS OF INTEREST

None of the authors have a conflict of interest.

GRANT SUPPORT

This study is supported (in part) by grants from the Dutch Cancer Society (RUG 2009-4279) to AvdB and BJK, the Pediatric Oncology Foundation Groningen (SKOG 11-001) to JK and AvdB, and the Jan Kornelis de Cock Foundation to ISP.

REFERENCES

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*. 2004; 116: 281-297.
2. Musilova K, Mraz M. MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. *Leukemia*. 2015; 29: 1004-1017.
3. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, Friendewey D, Valenzuela D, Kutok JL, Schmidt-Supprian M, Rajewsky N, Yancopoulos G, et al. Regulation of the germinal center response by microRNA-155. *Science (New York, N.Y.)*. 2007; 316: 604-608.
4. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, Croce CM. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2006; 103: 7024-7029.
5. Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, Slack FJ. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*. 2012; 109: E1695-704.
6. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraei N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. *Blood*. 2013; 122: 1891-1899.
7. Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, Kroesen BJ, van den Berg A. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. *The Journal of pathology*. 2005; 207: 243-249.
8. van den Berg A, Kroesen BJ, Kooistra K, de Jong D, Briggs J, Blokzijl T, Jacobs S, Kluiver J, Diepstra A, Maggio E, Poppema S. High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma. *Genes, chromosomes & cancer*. 2003; 37: 20-28.
9. Kluiver J, Haralambieva E, de Jong D, Blokzijl T, Jacobs S, Kroesen BJ, Poppema S, van den Berg A. Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. *Genes, chromosomes & cancer*. 2006; 45: 147-153.
10. Teng G, Hakimpour P, Landgraf P, Rice A, Tuschl T, Casellas R, Papavasiliou FN. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. *Immunity*. 2008; 28: 621-629.
11. O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. *Proceedings of the National Academy of Sciences of the United States of America*. 2009; 106: 7113-7118.
12. Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S, Das PP, Miska EA, Rodriguez A, Bradley A, Smith KG, Rada C, Enright AJ, et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. *Immunity*. 2007; 27: 847-859.
13. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell*. 2005; 120: 15-20.
14. Deng N, Puetter A, Zhang K, Johnson K, Zhao Z, Taylor C, Flemington EK, Zhu D. Isoform-level microRNA-155 target prediction using RNA-seq. *Nucleic acids research*. 2011; 39: e61.
15. Meier J, Hovestadt V, Zapatka M, Pscherer A, Lichter P, Seiffert M. Genome-wide identification of translationally inhibited and degraded miR-155 targets using RNA-interacting protein-IP. *RNA biology*. 2013; 10: 1018-1029.
16. Kluiver J, Gibcus JH, Hettinga C, Adema A, Richter MK, Halsema N, Slezak-Prochazka I, Ding Y, Kroesen BJ, van den Berg A. Rapid generation of microRNA sponges for microRNA inhibition. *PloS one*. 2012; 7: e29275.
17. Brown BD, Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. *Nature reviews Genetics*. 2009; 10: 578-585.
18. Ebert MS, Sharp PA. MicroRNA sponges: progress and

- possibilities. *RNA* (New York, N.Y.). 2010; 16: 2043-2050.
19. Dorsett Y, McBride KM, Jankovic M, Gazumyan A, Thai TH, Robbiani DF, Di Virgilio M, Reina San-Martin B, Heidkamp G, Schwickert TA, Eisenreich T, Rajewsky K, Nussenzweig MC. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. *Immunity*. 2008; 28: 630-638.
 20. Bouamar H, Jiang D, Wang L, Lin AP, Ortega M, Aguiar RC. MicroRNA 155 control of p53 activity is context dependent and mediated by Aicda and Socs1. *Molecular and cellular biology*. 2015; 35: 1329-1340.
 21. Hagen J, Tompkins V, Dudakovic A, Weydert JA, Quelle DE. Generation and characterization of monoclonal antibodies to NIAM: a nuclear interactor of ARF and Mdm2. *Hybridoma* (2005). 2008; 27: 159-166.
 22. Tompkins VS, Hagen J, Frazier AA, Lushnikova T, Fitzgerald MP, di Tommaso A, Ladeveze V, Domann FE, Eischen CM, Quelle DE. A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability. *The Journal of biological chemistry*. 2007; 282: 1322-1333.
 23. Reed SM, Hagen J, Tompkins VS, Thies K, Quelle FW, Quelle DE. Nuclear interactor of ARF and Mdm2 regulates multiple pathways to activate p53. *Cell cycle* (Georgetown, Tex.). 2014; 13: 1288-1298.
 24. Reed SM, Hagen J, Muniz VP, Rosean TR, Borchering N, Sciegienka S, Goeken JA, Naumann PW, Zhang W, Tompkins VS, Janz S, Meyerholz DK, Quelle DE. NIAM-Deficient Mice Are Predisposed to the Development of Proliferative Lesions including B-Cell Lymphomas. *PLoS one*. 2014; 9: e112126.
 25. Tompkins VS, Hagen J, Frazier AA, Lushnikova T, Fitzgerald MP, di Tommaso A, Ladeveze V, Domann FE, Eischen CM, Quelle DE. A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability. *The Journal of biological chemistry*. 2007; 282: 1322-1333.
 26. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2008.
 27. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood*. 2004; 103: 275-282.
 28. Slezak-Prochazka I, Kluiver J, de Jong D, Kortman G, Halsema N, Poppema S, Kroesen BJ, van den Berg A. Cellular localization and processing of primary transcripts of exonic microRNAs. *PLoS one*. 2013; 8: e76647.
 29. Pajic A, Spitkovsky D, Christoph B, Kempkes B, Schuhmacher M, Staeger MS, Brielmeier M, Ellwart J, Kohlhuber F, Bornkamm GW, Polack A, Eick D. Cell cycle activation by c-myc in a burkitt lymphoma model cell line. *International journal of cancer. Journal international du cancer*. 2000; 87: 787-793.
 30. Mao TK, Chen CZ. Dissecting microRNA-mediated gene regulation and function in T-cell development. *Methods in enzymology*. 2007; 427: 171-189.
 31. Kluiver J, Slezak-Prochazka I, van den Berg A. Studying microRNAs in lymphoma. *Methods in molecular biology* (Clifton, N.J.). 2013; 971: 265-276.
 32. Robertus JL, Harms G, Blokzijl T, Booman M, de Jong D, van Imhoff G, Rosati S, Schuurin E, Kluin P, van den Berg A. Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. 2009; 22: 547-555.
 33. Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. *The American journal of pathology*. 2001; 158: 419-429.
 34. Tan LP, Seinen E, Duns G, de Jong D, Sibon OC, Poppema S, Kroesen BJ, Kok K, van den Berg A. A high throughput experimental approach to identify miRNA targets in human cells. *Nucleic acids research*. 2009; 37: e137.
 35. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic acids research*. 2002; 30: 207-210.
 36. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102: 15545-15550.
 37. Gibcus JH, Tan LP, Harms G, Schakel RN, de Jong D, Blokzijl T, Moller P, Poppema S, Kroesen BJ, van den Berg A. Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile. *Neoplasia* (New York, N.Y.). 2009; 11: 167-176.
 38. Winkle M, van den Berg A, Tayari M, Sietzema J, Terpstra M, Kortman G, de Jong D, Visser L, Diepstra A, Kok K, Kluiver J. Long noncoding RNAs as a novel component of the Myc transcriptional network. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2015; 29: 2338-2346.